Fischer R

No ORCID on file · 13 papers in corpus · active 1963-2026

Study types

  • other 6
  • review 2
  • article 1

Condition tags

  • endometriosis 2
  • infertility 1
other 2026
Gynecologic and obstetric investigation ·doi:10.1159/000550420

INTRODUCTION: Investigation of the number of oocytes recovered from different ovarian stimulation (OS) protocols is essential, as oocyte number is positively associated with the number of good-quality embryos obtained; however, there are fe…

other 2025
Fertility and sterility ·doi:10.1016/j.fertnstert.2024.10.001

OBJECTIVE: To assess the adequate ovarian follicular development and oocyte recovery between ovarian potential (antral follicle count [AFC]) before the start of ovarian stimulation (OS) and oocyte quantity and quality at oocyte retrieval. A…

other 2024
Reproductive biomedicine online ·doi:10.1016/j.rbmo.2023.103725

RESEARCH QUESTION: According to real-world data, is recombinant human FSH (r-hFSH) combined with recombinant human LH (r-hLH) or r-hFSH alone more effective for women of advanced maternal age (AMA) in terms of live birth? DESIGN: Non-inter…

other 2024
Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-024-01291-x

BACKGROUND: Currently, there is no consensus on the optimal management of women with low prognosis in ART. In this Delphi consensus, a panel of international experts provided real-world clinical perspectives on a series of literature-suppor…

other 2023
Gynecologic and obstetric investigation ·doi:10.1159/000530360

OBJECTIVES: The aim of the study was to evaluate dosing of recombinant human luteinizing hormone (r-hLH) or human menopausal gonadotrophin (hMG)-derived medications with LH activity in ovarian stimulation (OS) cycles for in vitro fertilizat…

review 2023
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2023.102350

This non-interventional study compared the effectiveness of recombinant human follicle-stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) (2:1 ratio) versus r-hFSH alone for ovarian stimulation (OS) during assist…

other 2022
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2022.02.002

This was a retrospective real-world evidence analysis of the costs per live birth for reference recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG-HP), based o…

2021
Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-021-00768-3

BackgroundThis study compared the effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa; GONAL-f®) with urinary highly purified human menopausal gonadotropin (hMG HP; Menogon HP®), during assisted reproductive te…

2020
Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-020-00605-z

The prolonged lockdown of health services providing high-complexity fertility treatments -as currently recommended by many reproductive medicine entities- is detrimental for society as a whole, and infertility patients in particular. Global…

2019
Nature genetics ·doi:10.1038/s41588-018-0286-6

To further dissect the genetic architecture of colorectal cancer (CRC), we performed whole-genome sequencing of 1,439 cases and 720 controls, imputed discovered sequence variants and Haplotype Reference Consortium panel variants into genome…

2015
BMJ open ·doi:10.1136/bmjopen-2015-008297

IntroductionThe results of a recent meta-analysis showed that adding recombinant human luteinising hormone (r-hLH) to recombinant human follicle-stimulating hormone (r-hFSH) for ovarian stimulation was beneficial in poor responders, resulti…

review 1977
Strahlentherapie

A review of the principles of histological classification of the malignant ovarian tumours is given. In the center of the discussion figure the tumours originating from the surface epithelium, which make up the majority of ovarian tumours. …

article 1963
Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen